Route of administration of biotech product Parenteral route mentioning Soluble carrier system & Particulate carrier system

1. PRESENTATION
T MY
A N M Sharif
anm.sharif@live.com

2. PRESENTATION ON
‘‘Route of administration of biotech
product:
Parenteral route mentioning Soluble
carrier system & Particulate carrier
system’’

3. Biotechnology Biotech Product
Route of
administration of
biotech products
Parenteral route
of administration
for biotech
products
Carrier system
drug delivery
Particulate carrier
system
Soluble carrier
system
Conclusion
OBJECTIVE
S

4. Use of living
systems,
organisms, or
parts of
organisms
to
manipulate
in the
genetic level
to develop
products,
systems or
environments to
benefit

5. produce new
substances
or perform
new
functions
to modify
the genetic
material of
living cells
made by
using
biotechnical
methods
BIOTECH PRODUCTS

6. Methods to produce biotech
products
• Recombinant DNA
technology
• Fermentation
• Tissue or cell culture
technology
• Genetic engineering

7. •Avastin
Antibod
y
•Orenci
Fusion
protein
•Leukine
Progenitor
cells
stimulator

8. ROUTES OF
ADMINISTRATION
OF BIOTECH
PRODUCTS
Parenteral
route
Oral route
Nasal route
Trans-mucosal
route

9. Parenteral Route
of Administration
• Intravenou
IV
• Intramuscular
IM
• Subcutaneou
SC

10. Intravenous Administration
Fastest way
Directly in one of superficial vein
Highest concentration can be achieved

11. common with
biotechnology-derived
drugs, particularly those
used to treat chronic
conditions
Administered as a
bolus into the
subcutis
the layer of skin
directly below the
dermis and
epidermis,
collectively
referred to as the
cutis
Subcutaneous Administration
Example
Rheumatoid
Arthritis
Products
Etanercept
Anakinra
Adalimumab
Insulin and
hormones
administered
as
subcutaneous
injection

12. INTRAMASCULAR
ADMINISTRATION
• Intramuscular administration of
biotechnology-derived drugs is also
commonly seen
• A technique used to deliver a medication
into the muscles
• e.g. interferon β products have been shown
to be less immunogenic when administered
via intramuscular injection.

13. Advantages
Rapid administration of
solution
Avoids first pass
metabolism
100% bioavailable
Prevent the growth of
cancerous cells

14. IV
nutrient
therapy

15. Disadvantage
Painful & Fearful
Infection
Supervisor required to
administer

16. Disadvantage
Irreversible Coagulation

17. CARRIER SYSTEM
Biochemically
inert (non-toxic)
Non-
immunogen
ic
Physically and
chemically stable in
vivo and in vitro
conditions
Carrier systems
convey drugs to
specific receptors
and ligands and
physically modulate
components.

18. Overview of carrier system
drug delivery

19. CARRIER SYSTEM

20. PARTICULATE CARRIER SYSTEM
PARTICULATE
CARRIERSYSTEM
Microspheres
Microcapsules
Nanoparticles
Aquasomes
Liposomes
Emulsions
Cellular carriers

21. Microspheres
Conjugating
receptor
specific
moieties
Protein
Targeting

22. Microspheres
Advantage
• Cheap preparation
• implantation not
Passage through barriers

23. Microspheres
Disadvantage
release
maybe
difficul
Prossible
interactio
with
compone
ts

24. Microcapsules
Control
release of
peptides
moieties
polymeric
in nature
interfacial
polymeriza
tion
or
coacervate
phase
separation
Permeabilit
y barrier

25. Microcapsules
Conventionall
y used
polymers
Nylon
Gelatin
PVA
Polyurethane

26. Nanoparticles
Similar to
microspheres
targeted
delivery
specificity and
enhancement
effective
adjuvant
Methods
Conventional solution
Desolvation
in situ micellar
polymerization

27. Nanoparticles
Example
Cyanoacrylate
Polymethacrylate
Polystyrene
Albumin
Acrylic resins

28. Aquasomes
self-
assembling
nanoconstruct
Immobilizatio
of bioactive
molecules
Example: Aquasome-delivered
insulin

29. Lipsomes
Spherical
vesicles
concentric
bilayers
surrounding
aqueous
phases
Methods DRV
Reverse phase
evaporation

30. Lipsomes
Flexibility
nontoxic deposition
peptide and protein encapsulation
adjuvants

31. Emulsions
Colloid
sized
droplets
protection
from body
fluids
clinical
acceptability
large scale
production

32. Cellular carriers
Methods
Erythrocytes
encapsulation
hemolysis
dialysis
electric field breakup

33. Soluble carrier system
The peptide /protein drugs can be
conjugate with a
polymer/macromolecule

34. PEGylation
Glycosylation
Mannosylation
Others

35. PEGylation:
 The attachment of PEG with therapeutic protein

36. Glycosylation
The attachment of
sugar moieties to
protein to form
glycoprotein

37. Mannosylation:
 Conjugation of protein with Mannose

38. On-demand
system
Self-regulated
system
Temper
sensitive system
Pumps
Mechanical
pump
osmotic
pump
Control release
micro-pump
Other
s

39. For improving therapeutic
efficacy
Overcoming drawbacks
associated with conventional
dosage form.
Replacing existing
traditional pharmaceuticals.
Conclusion

40.  Almeida H, Amaral MH, Lobão P. Drugs Obtained by Biotechnology Processing.
Brazilian Journal of Pharmaceutical Sciences, 2011; 47(2): 199-207.
 Manda R, Dr. Suthakaran R, Kaya V, Fouziya BS. A Comparative Review of
Recently Developed Particulate Drug Carrier Systems. World Journal of
Pharmacy and Pharmaceutical Sciences, 2014; 3(11): 121-134.
 Nagel Km, Karash AR. Biotechnology. In Lee M, Desai A, Editors. Gibaldi’s Drug
Delivery Systems in Pharmaceutical Care. American Society of Health-System
Pharmacists, Inc., 2007; pp 135-154.
 Patel A, Cholkar K, Mitra AK. Recent developments in protein and peptide
parenteral delivery approaches. Ther. Deliv., 2014; 5(3): 337–365.
 Srikanth K, Gupta VRM, Manvi SR, Devanna N. Particulate Carrier Systems: A
Review. International Research Journal of Pharmacy, 2012; 3(11): 22-26.
REFERENCES